BioNTech SE (WBO:BNTX) Total Liabilities : €2,760 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is BioNTech SE Total Liabilities?

BioNTech SE's Total Liabilities for the quarter that ended in Dec. 2023 was €2,760 Mil.

BioNTech SE's quarterly Total Liabilities increased from Jun. 2023 (€2,319.10 Mil) to Sep. 2023 (€2,340.40 Mil) and increased from Sep. 2023 (€2,340.40 Mil) to Dec. 2023 (€2,760.40 Mil).

BioNTech SE's annual Total Liabilities declined from Dec. 2021 (€3,937.10 Mil) to Dec. 2022 (€3,223.50 Mil) and declined from Dec. 2022 (€3,223.50 Mil) to Dec. 2023 (€2,760.40 Mil).

BioNTech SE Total Liabilities Historical Data

The historical data trend for BioNTech SE's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNTech SE Total Liabilities Chart

BioNTech SE Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

304.16

946.80

3,937.10

3,223.50

2,760.40

BioNTech SE Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															3,223.50	1,813.70	2,319.10	2,340.40	2,760.40

BioNTech SE Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

BioNTech SE's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2070.5	+	(191	+	60.7
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	438.2	+	0)
	=	2,760

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	23006.3	-	20245.9
	=	2,760

BioNTech SE's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2070.5	+	(191	+	60.7
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	438.2	+	0)
	=	2,760

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	23006.3	-	20245.9
	=	2,760

BioNTech SE Total Liabilities Related Terms

Thank you for viewing the detailed overview of BioNTech SE's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

BioNTech SE (WBO:BNTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (WBO:BNTX) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

BNTX:USA BNTX:Mexico 0A3M:UK 22UA:Germany B1NT34:Brazil

Address

An der Goldgrube 12, Mainz, RP, DEU, D-55131

Website

https://www.biontech.de

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.